TABLE 1.

In vitro susceptibilities to 10 antimicrobial agents for clinical isolates of P. aeruginosa collected from 1999 to 2002a

Antimicrobial agent(s)Yr% Susceptible% Intermediate% Resistant
Non-ICUICUNHOPCombinedNon-ICUICUNHOPCombinedNon-ICUICUNHOPCombined
Amikacin199986.091.393.488.687.73.94.85.34.34.110.13.91.37.18.2
200088.987.992.383.886.84.67.03.16.65.76.45.14.69.67.5
200191.889.595.282.188.73.83.43.15.84.34.47.21.712.16.9
200292.189.693.088.590.83.44.54.84.54.04.55.92.27.05.2
1999-200290.689.494.085.489.03.84.84.05.44.45.55.72.09.26.6
Cefepime199975.679.581.682.778.413.313.517.111.712.911.17.01.35.68.8
200075.366.976.978.575.313.117.315.412.413.511.615.77.79.111.2
200177.373.473.178.877.013.514.919.312.613.89.211.77.68.69.2
200275.764.272.983.476.414.919.018.410.614.39.416.88.76.09.2
1999-200276.169.673.380.776.613.916.718.711.813.810.013.77.97.59.5
Ceftazidime199977.983.292.186.981.55.24.53.94.74.917.012.43.98.413.6
200076.972.984.686.179.97.78.13.14.76.615.419.012.39.213.5
200175.272.257.083.576.211.19.626.36.310.613.618.216.710.213.2
200275.065.064.085.876.311.913.522.67.211.413.121.613.46.912.3
1999-200275.871.562.185.377.610.09.823.36.19.414.218.714.68.713.0
Ciprofloxacin199961.674.460.562.363.810.56.96.610.19.827.918.832.927.626.5
200062.466.669.266.664.76.74.51.57.76.730.928.929.225.728.6
200160.567.543.064.461.15.85.18.68.46.833.627.348.427.332.1
200259.657.944.166.560.45.44.310.46.45.935.037.845.527.133.7
1999-200260.765.044.765.461.96.45.09.27.76.832.930.146.026.931.3
Gentamicin199971.973.069.770.971.89.910.318.410.310.218.216.711.818.818.0
200069.363.383.167.567.89.09.34.610.59.621.727.412.321.922.6
200174.975.368.467.172.08.36.113.210.09.016.818.618.423.019.0
200272.969.465.276.072.910.88.416.49.210.416.322.118.414.816.7
1999-200272.870.167.270.771.59.68.314.79.99.817.621.618.119.518.7
Imipenem199976.780.485.583.679.46.03.93.96.85.917.315.710.59.514.7
200077.873.587.786.480.64.55.61.54.04.417.720.810.89.615.0
200179.075.870.184.579.77.45.118.44.77.113.719.211.510.813.1
200276.768.271.086.678.27.75.018.25.17.415.626.810.88.314.4
1999-200277.673.371.485.579.36.85.017.54.96.515.621.711.19.514.2
Piperacillin199981.185.694.790.184.6-b----18.914.45.39.915.4
200080.877.084.688.483.2-----19.223.015.411.616.8
200183.577.282.287.183.9-----16.522.817.812.916.1
200283.573.582.991.184.5-----16.526.517.18.915.5
1999-200282.777.183.089.184.1-----17.322.917.010.915.9
Piperacillin-tazobactam199983.288.898.792.787.0-----16.811.21.37.313.0
200085.384.592.391.287.5-----14.715.57.78.812.5
200189.385.988.990.989.4-----10.714.111.19.110.6
200289.385.189.694.390.3-----10.714.910.45.79.7
1999-200287.885.789.692.389.1-----12.214.310.47.710.9
Ticarcillin-clavulanate199970.372.188.276.772.6-----29.727.911.823.327.4
200068.965.178.579.672.5-----31.134.921.520.427.5
200165.865.644.577.768.0-----34.234.455.522.332.0
200265.856.950.780.167.9-----34.243.149.319.932.1
1999-200266.963.449.778.869.4-----33.136.650.321.230.6
Tobramycin199987.688.194.785.687.22.01.51.32.82.110.410.53.911.610.7
200084.279.290.884.983.82.41.41.53.02.513.419.57.712.113.8
200185.884.780.481.583.92.00.75.13.32.512.214.614.415.213.5
200286.482.483.889.086.51.51.02.41.91.712.116.613.99.111.8
1999-200286.083.182.785.385.31.91.13.62.72.112.115.813.712.012.6
  • a The percentages of susceptible, intermediate, and resistant isolates according to NCCLS breakpoints are shown. P. aeruginosa isolates were collected from non-ICU patients, ICU patients, nursing home (NH) patients, outpatients (OP), and all patients combined. The total numbers of isolates collected from non-ICU patients, ICU patients, NH patients, OP, and all patients from 1999 to 2002 follow: in 1999, 3,388, 963, 76, 1,847, and 6,274, respectively; in 2000, 4,442, 1,391, 65, 3,728, and 9,626, respectively; in 2001, 7,923, 1,577, 1,185, 4,975, and 15,660, respectively; in 2002, 9,896, 2,163, 1,269, 5,444, and 18,772, respectively. For all isolates collected in 1999 to 2002, the total numbers of isolates collected from non-ICU patients, ICU patients, NH patients, OP, and all patients combined were 25,649, 6,094, 2,595, 15,994, and 50,332, respectively.

  • b -, NCCLS breakpoints for the susceptible, intermediate, and resistant categories unavailable.